BioMarin updates financial impact of Inozyme Pharma acquisition with estimated 221 million charge in Q3 2025
BioMarin Pharmaceutical Inc. anticipates a charge of approximately $221 million in Q3 2025 due to its acquisition of Inozyme Pharma, Inc. on July 1, 2025. This charge is expected to affect both GAAP and Non-GAAP diluted earnings per share by about $1.10 each. The figures are preliminary and subject to final financial statement procedures for the quarter ending September 30, 2025.
BioMarin Pharmaceutical Inc. expects to record acquired in-process research and development (IPR&D) charges of approximately $221 million in the third quarter of 2025 following its acquisition of Inozyme Pharma, Inc. on July 1, 2025. This charge is estimated to impact both GAAP and Non-GAAP diluted earnings per share by about $1.10 each. BioMarin noted that these figures are preliminary and subject to final financial statement closing procedures for the quarter ended September 30, 2025. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMarin Pharmaceutical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001048477-25-000101), on October 07, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
